Edison Investment Research - Shore Capital Group PLC (SGR) Navigating uncertainty

Report

Edison Investment Research

Andrew Mitchell

Navigating uncertainty

2016 saw revenue progress in both of the core operating divisions of Capital Markets and Asset Management. Stripping out the inevitable volatile items with Principal Finance (radio spectrum licence sale in 2015 and asset write-downs in 2016), adjusted group revenue grew 21% and adjusted earnings at 13.4p (2015: 12.1p) were more than double the reported level. The progress illustrates the benefits of diversification and continuing investment in additional staff to strengthen the research franchise and support growth in asset management.

11/04/2017 12 EN

Underlying

Shore Capital Group PLC

Shore Capital Group is engaged in investment related activities, including stockbroking, market-making, corporate finance advice, asset management including specialist fund management and principal finance.

See profile

GG00BGCZJ741 United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Andrew Mitchell

Other Reports on these Companies

GlobeNewsWire

Form 8.5 (EPT/RI) - Sirius Minerals Plc

Form 8.5 (EPT/RI) - Sirius Minerals Plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeSirius Minerals Plc(c) Name of the party to the offer with which exempt principal trader is connected:Sirius Minerals Plc(d) Date dealing un...

March 6, 2020 March 6, 2020 1 EN

SmartInsider

1 director bought

A director at Shore Capital Group Ltd bought 201,283 shares at 145p and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Free Trial

October 16, 2019 October 16, 2019 1 EN

GlobeNewsWire

Director/PDMR Shareholding

Director/PDMR Shareholding Shore Capital Group Limited (“Shore Capital” or the “Company”) Director/PDMR Shareholding Shore Capital was notified today that Elizabeth van Messel, the wife of Michael van Messel, a Senior Executive of the Company, has bought 201,283 ordinary shares of no par value in the Company ("Ordinary Shares") at a price of £1.45 per share (the "Purchase"). Following the Purchase, Michael van Messel and connected persons' beneficial interest in the Company is 967,127 Ordinary Shares, representing approximately 4.48% of the issued share capital of the Company. The noti...

October 16, 2019 October 16, 2019 1 EN

AGBA - A transformational deal

On 18 April, AGBA announced a surprise deal to acquire 100% of Triller Corp, a global AI-driven social video platform, in an all-stock transaction. Triller is privately-owned but has been independently valued at US$3.2bn. AGBA’s management is using a US$4bn valuation for the combined entity, in which AGBA shareholders will own 20% and Triller shareholders 80%. Triller recorded FY23 revenues of US$45m on 450m user accounts and 2.2m creators but is loss-making. In FY23, AGBA reported revenues of US$54m and 400,000+ clients. The combined group expects synergies from expanding and marketing to Tri...

6h / 42m 6h / 42m 1 EN

Sean Conroy

Sean Conroy

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

10h / 52m 10h / 52m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

April 25, 2024 April 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN